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In 2007, Zhao et al. [1] proposed a unified genetic theory
of sporadic and inherited autism spectrum disorders to
explain the complex familial patterns observed. The model
explains why most families have a low risk of autistic chil-
dren with an overall incidence rate of approximately 1 in
150 births, but a small minority of families have a 50% risk
for male offspring. Their model links these two risk classes
by their genetic origins: sporadic autism in low-risk
families is mainly caused by highly penetrant spontaneous
mutations in autism-related genes, whereas inherited aut-
ism in high risk families is mainly caused by unaffected
parents carrying a causative mutation that is transmitted
in a dominant fashion to their offspring. The evidence for
the model was based on the available genotyping assays
that showed an elevated rate of de novo copy number var-
iants (CNVs) in children with autism spectrum disorders.
Since then, we and other collaborators have been fol-
lowing up with a high-resolution exome sequencing
study of 2,800 families from the Simons Simplex Collec-
tion to pinpoint the genetic components of the disorder.
Unlike the early studies that could only detect large copy
number events spanning tens or hundreds of thousands
of basepairs across multiple genes, our new study has
power to examine single nucleotide and indel mutations
within individual genes. From our preliminary analysis of
approximately 350 of these families [2], as well as the
reports of three other groups, we have collected strong
evidence for the role of’likely gene-disrupting’(LGD)
mutations (nonsense, splice site and frame shifts), with
affected individuals having twice as many LGDs com-
pared to unaffected siblings, and five ‘double hit’ genes
(CHD8, DYRK1A, KATNAL2, POGZ, SCN2A) having two
de novo mutations in unrelated individuals. From this
analysis, we estimate approximately 400 genes are targets
of autism spectrum disorders. Interestingly, from the
gene set we have already identified, we have discovered a
strong association between the targets LGD mutations in
autism and in vivo targets of the RNA-binding transla-
tional regulator FMRP (encoded by FMR1), which results
in Fragile X Syndrome when silenced or mutated. The
large number of samples in the study necessitated that
we develop a high performance parallel sequence analysis
pipeline that could scale to the large volume of data and
make use of local disk storage. We were able to make use
of several existing tools for the preliminary analysis
(BWA, SAMTools, GATK, etc), and we also developed
additional components for genotyping within a family
and across the population using a multinomial statistical
approach. This includes a novel sequence analysis algo-
rithm for discovering insertion & deletion variants using
a localized sequence assembly approach that is superior
to standard mapping algorithms. We continue to refine
the algorithms to improve scalability, sensitivity, and spe-
cificity, and are beginning to apply it towards analyzing
the genomes of families with other complex cognitive
disorders.
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